Clinical Trials Logo

Clinical Trial Summary

To quantitatively analyze the total radioactivity in the excreta of healthy male subjects after oral administration of [14C] SPH3127, and determine the cumulative excretion rate and main excretion routes of radioactive substances; to investigate the partition in whole blood and plasma and the pharmacokinetics of total radioactivity in plasma after a single oral administration of [14C]SPH3127 in healthy male subjects; to identify the main metabolites in healthy male subjects after an oral administration of [14C] SPH3127, determine the main biotransformation pathways and main metabolites, quantitatively analyze the concentration of SPH3127 and main metabolites in plasma by validated LC-MS/MS method, and establish the pharmacokinetic parameters of SPH3127 and its main metabolites in plasma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05593562
Study type Interventional
Source Shanghai Pharmaceuticals Holding Co., Ltd
Contact
Status Completed
Phase Phase 1/Phase 2
Start date October 16, 2022
Completion date October 24, 2022